Current Drug Development Market for Cytokines Chemokines and Growth Factors

D&MD's Current Drug Development Market for Cytokines, Chemokines and Growth Factors focuses primarily on the cytokine market, company pipelines and trials in the field of cytokine research. This report succinctly details all the latest advances in the push to market of cytokine-based therapeutics: which products have evolved, which have failed and new players on the field. Primary readers will have comprehensive updates on relevant company pipelines.

Unique to this report is the comprehensive nature of compiled biological response modifiers currently in clinical testing. From the many interleukins to the vast array of growth factors, most all currently developed monoclonals, diabodies, soluble receptors, vaccines, small molecule antagonists, peptide mimetics, recombinantly altered antigens, as well as RNA interference and gene therapy vectors and plasmids are covered.

Also unique is the easy reference tables provided for "at-a-glance" assessment of developmental pipeline progress.

Market projection

The authors estimate that 2008 biopharma sales statistics covering cytokines will be in the range of:

Total world market, in terms of corporate revenues from biopharmaceutical sales, is probably about $80 - 100 billion

The largest portion of sales, of about 50 - 60% involves recombinant proteins, including recombinant monoclonal antibodies. Interferon cytokine's sales alone currently account for $1billion in revenues and is forecast to reach $3.5 billion by the end of the decade. This represents a dramatic 75% increase in 2005 market estimates

Other major sectors in terms of sales are vaccines ($15 billion), and human plasma-derived proteins (~$10 billion), with all other biopharmaceuticals accounting for $10 or more billion in sales

There could well be another $5 billion in sales of miscellaneous biosimilars, as older cytokine recombinant patents expire

Overall, cytokine-based drug sales seem to account for ~20% of the world biopharmaceutical market

Report Benefits

Identify which companies continue to leverage cytokine-based drugs and which companies license off developed cytokine technologies

Examine details on which small biotech start-up R&D pipelines are seeking big pharma development on a cytokine to cytokine basis

Explore products that continue to advance in the FDA approval cycle, seeking expanded label-uses

Research novel and newly discovered cytokine applications and pathways, which are highlighted to facilitate future drug discovery.

Start-up ventures are given a firm footing in the vast landscape of cytokine drug discovery and development and big pharma will be informed as to which of the many small biotech companies may meet their partnering or acquisition needs.

Published: January, 2007

Pages: 233 Format PDF
Table of Contents
Price: $4,950.00 / GBP2,475.00